In combination therapy of a TKI and ICI, the TKI has been shown to enhance the tumor-suppressive effect of the ICI by inhibiting the immunosuppressive roles of vascular endothelial growth factor receptor (VEGFR) and MET [10]. Here, MET is linked to neoplasm.